Addex Therapeutics Ltd (ADXN)

Addex Therapeutics Ltd (ADXN) Healthcare & Pipeline Overview

Addex Therapeutics Ltd, a Swiss biopharmaceutical firm, specializes in developing oral small molecule allosteric modulators for G-protein coupled receptors to treat central nervous system disorders. Its pipeline includes programs for Parkinson's disease levodopa-induced dyskinesia, dystonia, epilepsy, and addiction, supported by strategic collaborations.

What Is the Investment Thesis for ADXN?

Addex Therapeutics Ltd operates as a development-stage biopharmaceutical company focused on novel small-molecule allosteric modulators for central nervous system (CNS) disorders. The investment thesis centers on the potential of its lead pipeline candidates, particularly Dipraglurant for Parkinson's disease levodopa-induced dyskinesia (PD-LID) and dystonia, and ADX71149 for epilepsy. Successful clinical progression and regulatory approval of these programs represent significant value drivers, potentially unlocking substantial market opportunities in areas with unmet medical needs. The company's strategy includes leveraging its expertise in G-protein coupled receptor modulation, a validated drug target class, to develop first-in-class or best-in-class therapies. Growth catalysts include positive data readouts from ongoing clinical trials, initiation of new trial phases, and the potential for new or expanded licensing agreements with larger pharmaceutical partners, similar to its existing collaborations with Janssen Pharmaceuticals Inc. and Indivior PLC. These partnerships provide non-dilutive funding and validation of its technology platform. However, as a development-stage entity, Addex faces inherent risks associated with clinical trial failures, regulatory hurdles, and the need for significant capital to fund research and development. The company's current financial metrics, including a -4398.5% profit margin and -4.8% gross margin, reflect its pre-revenue stage and reliance on external funding or milestone payments. The high beta of 1.91 indicates significant stock price volatility, typical for biotechnology companies in early development.

Based on FMP financials and quantitative analysis

ADXN Key Highlights

• Market Capitalization: $0.00 billion, reflecting its early development stage and limited market valuation.
• Profit Margin: -4398.5%, indicative of a pre-revenue biopharmaceutical company heavily investing in R&D.
• Gross Margin: -4.8%, consistent with a company that has not yet commercialized products and incurs operational costs without significant product revenue.
• Beta: 1.91, suggesting higher volatility compared to the broader market, typical for biotechnology stocks.
• Employee Count: 2, highlighting a lean operational structure focused on core R&D and partnership management.

Who Are ADXN's Competitors?

ADXN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ADXN's Key Strengths?

• Specialized focus on G-protein coupled receptor (GPCR) allosteric modulation for CNS disorders.
• Proprietary pipeline with lead programs addressing significant unmet medical needs (PD-LID, epilepsy, addiction).
• Validated by existing license and collaboration agreements with major pharmaceutical companies (Janssen, Indivior).
• Lean operational structure with a focused R&D approach.

What Are ADXN's Weaknesses?

• Development-stage company with no commercialized products and negative profit/gross margins.
• High reliance on external funding or milestone payments due to pre-revenue status.
• Small employee base (2 employees) may limit internal capacity and breadth of operations.
• High clinical trial risk inherent in biopharmaceutical development.

What Could Drive ADXN Stock Higher?

• Positive clinical trial data readouts for Dipraglurant in Parkinson's disease levodopa-induced dyskinesia or dystonia.
• Initiation of later-stage clinical trials for ADX71149 in epilepsy or other CNS disorders.
• Announcement of new or expanded strategic licensing and collaboration agreements for pipeline assets.
• Continued progression of the GABAB PAM program through preclinical and early clinical development for addiction.
• Management of existing collaborations with Janssen Pharmaceuticals Inc. and Indivior PLC to achieve development milestones.

What Are the Key Risks for ADXN?

• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• High clinical trial failure rates inherent in biopharmaceutical development, particularly for CNS disorders.
• Significant capital requirements to fund ongoing research and development, potentially leading to future equity dilution.
• Intense competition from established pharmaceutical companies and other biotechnology firms developing CNS therapies.
• Regulatory hurdles and potential delays in obtaining marketing approvals for its drug candidates.
• Dependence on successful execution and management of existing and future collaboration agreements.

What Are the Growth Opportunities for ADXN?

• Growth opportunity 1: Advancement of Dipraglurant for Parkinson's Disease L-Dopa-Induced Dyskinesia (PD-LID): Dipraglurant, an mGlu5 negative allosteric modulator, represents a significant growth opportunity. PD-LID is a debilitating side effect affecting a substantial portion of Parkinson's patients on long-term levodopa therapy, with limited effective treatments currently available. The global Parkinson's disease market is projected to reach over $6 billion by 2027, with a significant segment dedicated to managing motor complications. Successful progression through clinical trials and eventual market approval for Dipraglurant could position Addex to capture a meaningful share of this specialized market, offering a novel therapeutic option and potentially improving patient quality of life. The competitive advantage lies in its specific mechanism of action, which aims to reduce dyskinesia without compromising levodopa's anti-parkinsonian effects.
• Growth opportunity 2: Development of ADX71149 for Epilepsy and Undisclosed CNS Disorders: ADX71149, a GABAB positive allosteric modulator, holds promise for epilepsy and other CNS indications. Epilepsy affects millions worldwide, with a global market size expected to exceed $8 billion by 2028, and a significant portion of patients remaining refractory to existing treatments. By targeting the GABAB receptor, ADX71149 could offer a differentiated approach to seizure control and other neurological conditions. The broad applicability of GABAB modulation suggests potential for expansion into multiple CNS indications, thereby diversifying Addex's pipeline and market reach. Successful clinical development could lead to a valuable asset, either for in-house commercialization or through further licensing agreements, tapping into a large and persistent patient population requiring new therapeutic options.
• Growth opportunity 3: Expansion of GABAB PAM Program for Addiction: The GABAB PAM (Positive Allosteric Modulator) program, focused on addiction, addresses another critical unmet medical need. Addiction, encompassing substance use disorders, represents a vast and underserved market, with significant societal and economic costs. While specific market size data for GABAB PAMs in addiction is emerging, the broader addiction treatment market is substantial and growing. Developing an effective GABAB PAM could offer a novel pharmacological approach to reduce cravings and relapse, potentially complementing or improving upon existing treatments. This program leverages Addex's expertise in GPCR modulation, offering a unique competitive angle in a therapeutic area where innovation is highly sought after. Successful development could lead to a breakthrough therapy with a large addressable patient population.
• Growth opportunity 4: Strategic Partnerships and Licensing Agreements: Addex's existing collaborations with Janssen Pharmaceuticals Inc. and Indivior PLC demonstrate a proven ability to attract and secure partnerships with larger pharmaceutical companies. These agreements provide not only non-dilutive funding through milestone payments but also access to extensive development and commercialization resources. Future growth can be significantly accelerated by forging new licensing deals for existing pipeline assets or for novel compounds emerging from its discovery platform. Such partnerships can de-risk development, expand geographic reach, and accelerate market entry, particularly for a company with a lean operational structure. The ability to form and maintain these alliances is a key competitive advantage in the capital-intensive biopharmaceutical industry.
• Growth opportunity 5: Leveraging Allosteric Modulator Platform for New Targets: Addex's core expertise lies in the discovery and development of oral small molecule allosteric modulators of G-protein coupled receptors. This proprietary platform represents a continuous source of potential new drug candidates beyond the current lead programs. The GPCR family is one of the largest and most therapeutically important classes of drug targets, implicated in a wide range of physiological processes and diseases. By continuously exploring new GPCR targets within CNS and potentially other therapeutic areas, Addex can replenish its pipeline and create future growth opportunities. This platform provides a sustainable competitive advantage, allowing the company to generate novel compounds with potentially superior selectivity and safety profiles compared to traditional orthosteric drugs, tapping into a vast and evolving drug discovery landscape.

What Opportunities Does ADXN Have?

• Successful advancement of lead programs (Dipraglurant, ADX71149, GABAB PAM) through clinical trials and regulatory approval.
• Expansion of existing partnerships or formation of new collaborations for pipeline assets.
• Potential to leverage its allosteric modulator platform to discover new drug candidates for additional CNS or other indications.
• Addressing large and growing markets with significant unmet medical needs in CNS disorders.

What Threats Does ADXN Face?

• Clinical trial failures or unexpected adverse events halting development of lead candidates.
• Intense competition from larger pharmaceutical companies and other biotechs in the CNS space.
• Regulatory hurdles and delays in obtaining marketing authorization.
• Need for substantial capital to fund R&D, potentially leading to dilution or financing challenges.

What Are ADXN's Competitive Advantages?

• Specialized expertise in developing small molecule allosteric modulators of G-protein coupled receptors (GPCRs), a complex and high-value area of drug discovery.
• Proprietary pipeline of novel drug candidates targeting significant unmet medical needs in CNS disorders, such as Dipraglurant and ADX71149.
• Established strategic collaborations with major pharmaceutical players like Janssen and Indivior, validating its technology and providing potential pathways for development and commercialization.
• Strong intellectual property surrounding its drug candidates and allosteric modulation platform.

What Does ADXN Do?

Founded in 2002 as Addex Pharmaceuticals Ltd, the company rebranded to Addex Therapeutics Ltd in March 2012, establishing its headquarters in Geneva, Switzerland. As a development-stage biopharmaceutical entity, Addex Therapeutics is dedicated to the discovery, development, and eventual commercialization of small-molecule pharmaceutical products specifically targeting central nervous system (CNS) disorders. The core of its scientific approach lies in the innovative discovery of oral small molecule allosteric modulators of G-protein coupled receptors (GPCRs). This focus positions Addex at the forefront of a specialized area of drug development, aiming to provide novel therapeutic options for complex neurological conditions. The company's pipeline is anchored by several lead programs, each addressing significant unmet medical needs. Dipraglurant is being developed for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID), a debilitating side effect of long-term levodopa therapy, and also for dystonia, a movement disorder characterized by sustained or repetitive muscle contractions. Another key program, ADX71149, is under investigation for epilepsy and other undisclosed CNS disorders, highlighting the broad applicability of Addex's modulator technology. Furthermore, the GABAB PAM program is focused on developing treatments for addiction, an area with substantial public health implications. Addex Therapeutics operates through a strategic model that includes both in-house research and development and collaborative partnerships. The company has established license and collaboration agreements with notable pharmaceutical entities such as Janssen Pharmaceuticals Inc. and Indivior PLC, which validate its scientific approach and provide potential pathways for broader development and commercialization. Additionally, a collaboration with The Charcot–Marie–Tooth Association underscores its commitment to addressing rare neurological conditions. Despite being a development-stage company with a lean operational structure, evidenced by its two employees, Addex maintains a global outlook through its partnerships, aiming to bring its innovative CNS therapies to patients beyond its Swiss base. Its evolution from a pure pharmaceuticals company to a therapeutics focus reflects a strategic refinement in its mission to deliver targeted treatments for CNS disorders.

What Products and Services Does ADXN Offer?

• Discovers and develops small-molecule drugs for central nervous system (CNS) disorders.
• Focuses on creating oral small molecule allosteric modulators of G-protein coupled receptors (GPCRs).
• Advances Dipraglurant for Parkinson's disease levodopa-induced dyskinesia (PD-LID) and dystonia.
• Develops ADX71149 for the treatment of epilepsy and other CNS conditions.
• Pursues a GABAB PAM program aimed at treating addiction.
• Engages in license and collaboration agreements with pharmaceutical partners like Janssen and Indivior.
• Conducts research and development from its headquarters in Geneva, Switzerland.

How Does ADXN Make Money?

• Primarily relies on milestone payments and potential royalties from license and collaboration agreements with larger pharmaceutical partners.
• Aims to generate revenue through the eventual commercialization of its proprietary drug candidates, either independently or through partnerships.
• Secures funding through equity financing to support ongoing research and development activities.

What Industry Does ADXN Operate In?

Addex Therapeutics Ltd operates within the highly specialized and competitive biotechnology industry, specifically focusing on central nervous system (CNS) disorders. This segment of the healthcare sector is characterized by significant unmet medical needs, high R&D costs, and lengthy drug development timelines. The global CNS therapeutics market is projected to experience steady growth, driven by an aging population and increasing prevalence of neurological conditions such as Parkinson's disease, epilepsy, and addiction. Addex's niche in developing small-molecule allosteric modulators of G-protein coupled receptors positions it within a cutting-edge area of pharmacology, aiming for therapies with potentially improved efficacy and safety profiles compared to orthosteric modulators. The competitive landscape includes large pharmaceutical companies with established CNS portfolios and numerous smaller biotechs developing novel treatments. Addex differentiates itself through its specific focus on allosteric modulation and its pipeline of distinct candidates like Dipraglurant and ADX71149, which target specific mechanisms within CNS pathways. Its strategic collaborations with major players like Janssen and Indivior provide a competitive edge by validating its technology and offering potential pathways for market access.

Who Are ADXN's Key Customers?

• Pharmaceutical companies seeking to license or collaborate on novel CNS drug candidates.
• Ultimately, patients suffering from central nervous system disorders such as Parkinson's disease, epilepsy, and addiction.
• Healthcare providers who would prescribe their approved therapies.

FY2026 estForward Outlook

Wall Street analysts project Addex Therapeutics Ltd revenue of about $1.4M for fiscal 2026, with EPS near $-4.74.

Quarterly Financial Performance: Addex Therapeutics Ltd

Revenue for Addex Therapeutics Ltd came in at $8K during Q1 2026, a 3070.2% improvement versus the preceding quarter. The company recorded a net loss of $1.7M, with diluted EPS of $-1.20. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, ADXN averaged $-1.70 in diluted EPS.

ADXN Valuation & Market Position

With a $4.13M market cap, Addex Therapeutics Ltd sits in the micro-cap segment of the market. Relative to its peer group, ADXN's quantitative score of 44/100 is below the peer average of 76/100.

Key Financial Metrics

Its free cash flow yield is -31.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.40 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -104.0%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 1/9Financial Health

Addex Therapeutics Ltd's Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

Company Profile

Addex Therapeutics Ltd operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Geneva, CH. The company is led by CEO Timothy Mark Dyer. ADXN has traded publicly since 2020.

ADXN Financials

ADXN Latest News

ADXN Analyst Consensus

ADXN MoonshotScore

What Investors Ask About Addex Therapeutics Ltd (ADXN) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources